Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 1073-1080

  McFadden, Karyn ^a   Fletcher, Patricia ^b   Rossi, Fiorella ^a   Kantharaju, ^a   Umashankara, Muddagowda ^a   Pirrone, Vanessa ^a   Rajagopal, Srivats ^a   Gopi, Hosahudya ^c   Krebs, Fred C ^a   Martin Garcia, Julio ^a   Shattock, Robin J ^b   Chaiken, Irwin ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HNG 156; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; TENOFOVIR; TRIAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ADENINE; ANTI-HIV AGENTS; CELL LINE; DRUG THERAPY, COMBINATION; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; ORGANOPHOSPHONATES; PEPTIDES; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES; VIRUS REPLICATION;

EID: 84856076358     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05555-11     Document Type: Article

References (57)

1. Abdool Karim Q, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-1174.
2. Allan JS, et al. 1985. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 228:1091-1094. (Pubitemid 15227368)
3. Balzarini J. 2007. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 5:583-597. (Pubitemid 47074114)
4. Barre-Sinoussi F, et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
5. Biorn AC, et al. 2004. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biochemistry 43:1928-1938. (Pubitemid 38233255)
6. Bullough PA, Hughson FM, Skehel JJ, Wiley DC. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43. (Pubitemid 24277462)
7. Chertova E, et al. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325. (Pubitemid 34517882)
8. Chou TC. 1976. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 59:253-276.
9. Chou TC, Talalay P. 1981. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur. J. Biochem. 115:207-216.
10. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
11. Daar ES, Li XL, Moudgil T, Ho DD. 1990. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci. U. S. A. 87:6574-6578.
12. Derdeyn CA, et al. 2004. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303:2019-2022. (Pubitemid 38393277)
13. Doncel G, Mauck C. 2004. Vaginal microbicides: a novel approach to preventing sexual transmission of HIV. Curr. HIV/AIDS Rep. 1:25-32.
14. Dorr P, et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732. (Pubitemid 41552605)
15. Earl PL, Koenig S, Moss B. 1991. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses. J. Virol. 65:31-41.
16. Ferir G, et al. 2011. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res. 90:200-204.
17. Ferrer M, Harrison SC. 1999. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 73:5795-5802. (Pubitemid 29274866)
18. Fisher RA, et al. 1988. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 331:76-78. (Pubitemid 18053420)
19. Gallo RC, et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-503. (Pubitemid 14134741)
20. Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R. 2004. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J. Mol. Biol. 340:9-14. (Pubitemid 38739433)
21. Garcia-Perez J, et al. 2011. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J. Biol. Chem. 286:4978-4990.
22. Gopi H, et al. 2009. Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120. J. Mol. Recognit. 22:169-174.
23. Gopi H, et al. 2008. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J. Med. Chem. 51:2638-2647. (Pubitemid 351620785)
24. Gopi HN, Tirupula KC, Baxter S, Ajith S, Chaiken IM. 2006. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120. Chem.MedChem 1:54-57. (Pubitemid 44104976)
25. Grant RM, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-2599.
26. Helseth E, Olshevsky U, Furman C, Sodroski J. 1991. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J. Virol. 65:2119-2123.
27. Keele BF, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105:7552-7557. (Pubitemid 351830056)
28. Kessler JA, II, et al. 1997. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 13:575-582.
29. Krebs FC, Miller SR, Malamud D, Howett MK, Wigdahl B. 1999. Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res. 43:157-173. (Pubitemid 29457438)
30. Layne SP, et al. 1992. Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 189:695-714.
31. Li M, et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125. (Pubitemid 41098552)
32. Li M, et al. 2006. Genetic and neutralization properties of acute and early subtype C human immunodeficiency virus type 1 molecular env clones from heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790. (Pubitemid 44788890)
33. McCune JM, et al. 1988. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55-67.
34. + T cells by a complex of the 110K viral protein and the T4 molecule. Science 231:382-385.
35. McFadden K, et al. 2007. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. Proteins 67:617-629. (Pubitemid 46625578)
36. Melikyan GB, et al. 2000. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151:413-423.
37. Mertenskoetter T, Kaptur PE. 2011. Update on microbicide research and development - seeking new HIV prevention tools for women. Eur. J. Med. Res. 16:1-6.
38. Moore JP, Sattentau QJ, Wyatt R, Sodroski J. 1994. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J. Virol. 68:469-484.
39. O'Keefe BR, et al. 2000. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. Mol. Pharmacol. 58:982-992.
40. Pirrone V, Thakkar-Rivera N, Jacobson JM, Wigdahl B, Krebs FC. 2011. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob. Agents Chemother. 55:1831-1842.
41. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J. Virol. 83:8289-8292.
42. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J. Virol. 72:2855-2864. (Pubitemid 28175522)
43. Pozniak A. 2008. Tenofovir: what have over 1 million years of patient experience taught us? Int. J. Clin. Pract. 62:1285-1293. (Pubitemid 351977619)
44. Robey WG, et al. 1985. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 228:593-595. (Pubitemid 15071408)
45. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T. 2006. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 352:477-484. (Pubitemid 44216012)
46. Salazar-Gonzalez JF, et al. 2008. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by singlegenome amplification and sequencing. J. Virol. 82:3952-3970. (Pubitemid 351521232)
47. Salazar-Gonzalez JF, et al. 2009. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206:1273-1289.
48. Sattentau QJ, Moore JP. 1991. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174:407-415.
49. Sattentau QJ, Zolla-Pazner S, Poignard P. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717.
50. Shattock RJ, Moore JP. 2003. Inhibiting sexual transmission of HIV-1 infection. Nat. Rev. Microbiol. 1:25-34.
51. Turpin JA. 2002. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Invest. Drugs 11:1077-1097.
52. Umashankara M, et al. 2010. The active core in a triazole peptide dual-site antagonist of HIV-1 gp120. ChemMedChem 5:1871-1879.
53. Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905. (Pubitemid 34535213)
54. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
55. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426-430. (Pubitemid 27227210)
56. Williamson C, et al. 2003. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res. Hum. Retroviruses 19:133-144. (Pubitemid 36308051)
57. Zhu P, et al. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U. S. A. 100:15812-15817. (Pubitemid 38021072)